Foundation Medicine
FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC - Lung Cancer Research Foundation
Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients | Business Wire
Companion Diagnostics Explained: Their Critical Role in Cancer Care and Our Latest Approvals | Foundation Medicine
HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings
FoundationOne Liquid CDx
FDA Approves FoundationOne CDx for Use with Bile Duct Cancer Treatment | Clinical Lab Products
Personalized Cancer Care with FoundationOne CDx - Nanalyze
Foundation Medicine receives FDA approval for pan-tumour biopsy test
Exhibitor Foundation Medicine 02-20 - Scripps CME Connection
Roche FMI landing page
Genomic profiling test
Companion Diagnostics Explained: Their Critical Role in Cancer Care and Our Latest Approvals | Foundation Medicine
FoundationOne® CDx - P170019/S017 | FDA
FoundationOne Liquid CDx – P190032 | FDA
Multi-gene Testing (NGS) for PIK3CA Mutations
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors | PLOS ONE
Compare Our Tests | Foundation Medicine
FDA Approves FoundationOne Liquid CDx for Advanced Cancer
Unlocking new treatment options for Patients with Metastatic Breast Cancer
Multi-gene Testing (NGS) for PIK3CA Mutations
